WilmerHale represented Volastra Therapeutics on the deal. Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), closed its $60 million Series...
Volastra Therapeutics’ $60M Series A Financing
Volastra Therapeutics’ Extended $44M Seed Financing
Wilmer Cutler Pickering Hale and Dorr LLP advised Volastra Therapeutics on the deal. Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment...